NCT03614052

Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy

Efectividad de la Tamsulosina Como Tratamiento Adyuvante Previo a Ureterolitotomia Endoscopica

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Pontificia Universidad Catolica de Chile · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This a study aiming to compare treatment with tamsulosin versus placebo in patients undergoing endoscopic treatment for urolithiasis. The main outcome is the rate of stone free patients.

Detailed description

Endoscopic treatment of urolithiasis has increased during the last several years. Adrenergic receptors have been described mainly in the distal ureter. Blockage of adrenergic receptors has been associated to a decrease in ureteral resistance. In this study the investigators hypothesized that alpha blockers are associated to a decrease in ureteral resistance with an increase in successful endoscopic management of urolithiasis. Only patients with urolithiasis undergoing to endoscopic treatment are offered to participate. Patients are randomized between placebo arm or tamsulosin 0.4 mg/day. Demographic characteristics, stones characteristics and information related to surgery are recorded. Main study outcome is stone free rate and successful insertion of semirigid ureteroscope 8,0 - 9,8 Fr. All patients are follow-up for 30 days after surgery.

Conditions

• Ureterolithiasis
• Ureteral Calculi
• Urolithiasis

Interventions

Type	Name	Description
DRUG	Tamsulosin Hydrochloride 0.4 milligrams	Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
DRUG	Placebo Oral Tablet	Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis

Timeline

• Start date: 2018-06-01
• Primary completion: 2020-01-26
• Completion: 2020-01-26
• First posted: 2018-08-03
• Last updated: 2020-01-31

Locations

1 site across 1 country: Chile